Last reviewed · How we verify
NCT05010590
Anabolic Therapy in Postmenopausal Osteoporosis
Phase 4 trial testing Romosozumab in Postmenopausal Osteoporosis in 50 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2027
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 24 March 2022 |
| Primary completion | 1 October 2027 |
| Estimated completion | 1 November 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Romosozumab (romosozumab) — full drug profile →
- Denosumab (DENOSUMAB) — full drug profile →
Conditions studied
- Postmenopausal Osteoporosis — all drugs for Postmenopausal Osteoporosis →
Sponsor
Massachusetts General Hospital
Who can join
45 and older, female only, with Postmenopausal Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.
Leder BZ, Ramchand SK, Jordan M, Ryan S, et al · · 2026 · cited 2× · PMID 41621431 · DOI 10.1016/s2213-8587(25)00319-5
Verify or expand the search:
- PubMed search for NCT05010590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Romosozumab
Trials testing the same drug.
- NCT07283887 — Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis · Phase 4 · recruiting
- NCT07384104 — Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in He · Phase 1 · enrolling by invitation
- NCT06558188 — Combined Anabolic Therapy · Phase 4 · recruiting
- NCT05972551 — Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Oste · Phase 3 · recruiting
- NCT06079476 — A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. · Phase 4 · completed
Other recruiting trials for Postmenopausal Osteoporosis
Currently open trials in the same condition.
- NCT02822378 — Dried Plums and Bone Health in Postmenopausal Women · NA · active not recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05010590 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05010590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing